Cardiomyopathy is a group of conditions that affect the structure of the heart and reduce its ability to pump blood around the body. Around 1 in 250 people in the UK are affected. This collaboration will see Picker redevelop and manage its national survey which aims to understand and improve the care experiences and support services for those living with cardiomyopathy.
Cardiomyopathy UK’s most recent UK-wide experience evaluation was conducted in 2022. The findings revealed areas for improvement in care delivery for those with cardiomyopathy. Following responses from 632 individuals, a need for better diagnosis, treatment, genetic testing, and wellbeing support was apparent.
Building on these findings, Cardiomyopathy UK and Picker will partner to increase the insight and impact of the 2024 programme. This iteration, called ‘My Insight’, will gather feedback from anyone affected by cardiomyopathy in the UK. Picker will lead the re-development of the experience evaluation and analysing, reporting the findings.
We are thrilled to support Cardiomyopathy UK in redeveloping and managing their 2024 survey. We will refine the survey to ensure that it gathers high quality and actionable data to uncover invaluable insights. These insights will not only inform service improvements but also foster a more supportive and compassionate care environment for all those affected by cardiomyopathy.
Cardiomyopathy UK is excited to undertake this research into people’s experiences of living with cardiomyopathy across the UK. Working with Picker will ensure this latest iteration of our biennial survey is of the highest quality. This will provide evidence to underpin our activities to drive improved access to quality care for everyone affected by cardiomyopathy. We will use the survey results to push for meaningful changes in prevention, diagnosis, treatment, support, wellbeing, and social care.
Ends
Notes for Editors